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Thirty-two patients with gastric cancer were treated by preoperative adjuvant 
chemotherapy with Mitomycin C (MMC), combined with side-effect-preventing 
agents, steroid hormone, VB6-P, reduced Glutathione and Cepharanthin⑧， dissolved 
in 500ml of 5% xylitol solution. MMC 6mg/day was given for ten days, a total of 
60mg. Changes in clinical findings, X-ray and endoscopic examinations were studied 
before and after the adjuvant chemotherapy. The excised specimen was microscopically 
examined to investigate degeneration of carcinoma caused by MMC chemotherapy. 
The results obtained are as follows : 
1. In the preoperative administration of MMC, side-effects complicating the 
operative treatment were not encountered. 
2. In regards to degeneration of cancer cel, adenocarcinoma tubulare, moderately 
differentiated but not scirrhus, showed a greater degree of degeneration, which 
was more marked in the muscular layer and the serous membrane than in the 
mucous membrane and the submucous tissue. 
3. A more advanced degeneration was found in the lymphnodes with metastasis 
than in the gastric wall infiltrated with carcinoma. 
4. X-ray and endoscopic examination after chemotherapy but before surgery 
revealed that in 13 cases the carcinoma legion appeared to become smaller, although 
there was no significant correlation between the post operative macro and 
microscopic pictures. 
In summary the auther concludes that the preoperative adjuvant chemotherapy 
as described in this paper may be an effective measure to improve the long-term 
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胃癌取扱い規約l引による Stage別分類では StageI 
15例， StageI 6伊U.Stage II 10例， StageIV 1 
例である（表1) . 






































































































































































































経過中での最低値を示すものが多く， 6例（症例 4,11, 投与前後の赤血球数を比較すると表 4，図11r.示す
12, 13, 21, 30) 18.7%に白血球減少が認められたが， 如くで， その平均値は投与前 439,6×104士42.6×104/
そのうち5週目まで白血球減少が続いたのは症例21の Cllil，投与直後 431×104士52.0×104/c皿，投与後1週
1例のみで，この症例も 7週自には正常値IC復してい 目464×104土57.8×104/cllil，投与後2週目434.4×10＇土
る．他l乙症例5の1例に5週目で白血球減少が認めら 51.0×104 /cllil，投与後3週目 402.5×104士48,4×104/
れた（表3，図 1) . C阻， 投与後4週目399.4×104士50.8×104/cllil, 投与




No. Pre. Post. Post. lw. I Post. 2w. ] P側 3w.I p側 4w.I Post. 5w. 
1 4,100 3,200 2,900 4,700 4,300 3,700 
2 5，α)0 5,800 11,600 5,600 5,800 
3 5,500 4,700 5,700 7,100 7,000 3,900 5,000 
4 6,900 5,400 10,700 4,600 4,900 2,100 3,400 
5 7,300 7,100 11,400 6,800 7,800 4,200 2,800 
6 6,700 4,900 8,600 9,900 7,700 3,300 4,900 
7 5,300 5,800 11,500 7,700 8,600 5,900 4,500 
8 8,300 6,300 6,600 7,100 5,900 5,500 8,200 
9 5,900 6,500 6,000 7,000 6,000 
10 6,300 8,200 11,400 7,400 7,400 9,500 8,900 
11 5,200 4,600 6,000 3,800 4,700 2.600 3,100 
12 4,500 7,800 5,500 4,200 3,400 1,200 4,100 
13 4,800 5,300 10,900 3,300 4,100 2,800 
14 6,400 3,900 9,000 4,300 1,900 11,400 19,500 
15 5,200 8,400 9,800 8,400 6,600 6,100 5,700 
16 5,700 4,700 5,200 7,900 7,700 
17 3.800 3,200 5,400 4,300 3,800 3,200 3,200 
18 4,600 5,900 4,600 7,500 4,800 3,200 4,000 
19 7.000 7,300 8,400 8,000 8,100 6,100 7,200 
20 6,600 5,000 7,600 7,900 9,600 6,500 3,500 
21 6,100 4,200 8,100 8,900 3,100 2,400 2,700 
22 4,500 5,000 5,100 8.800 7,100 6,400 4,400 
23 3,500 4,500 4,600 4,300 5,200 4,700 
24 5,400 5,900 4,500 6,000 4,300 4,000 
25 8,300 8,800 6,900 8,300 4,000 3,100 3,300 
26 6,900 5,300 5,500 6,100 6,600 4,700 4,200 
27 5,600 6,300 6,500 7,100 4,400 3,000 
28 6,400 5,600 3,300 2,500 1,300 4,000 6,500 
29 4,300 5,600 5,400 6,700 5,700 5,600 5,100 
30 6,800 5,800 4,800 6,800 4,600 1,700 6,900 
31 6,100 5,000 9,100 7,000 5,400 4,400 
32 6,300 6,100 12,000 6,800 3,300 
M 5,864 5,659 7,216 6,603 5,584 4,144 4,987 












No. Pre. Post. P凶 lw.I Post. 2w. P州 3w. Post. 4w. I Post. 5w. 
1 391×10' 370×1Q4 444×104 399メ104 3×104'¥ 408×104 
2 518 493 541 433 414 388 
3 437 473 522 446 401 374 371 
4 420 433 450 371 355 354 381 
5 524 510 599 432 477 446 437 
6 466 432 569 530 512 496 526 
7 434 419 507 446 407 412 406 
8 463 437 363 355 358 370 408 
9 458 437 450 387 365 400 429 
10 430 423 534 488 414 401 415 
11 464 453 458 439 380 
12 486 518 531 420 384 363 420 
13 359 449 443 430 489 
14 413 375 460 357 345 430 468 
15 539 514 563 483 427 370 402 
16 428 429 452 420 406 427 
17 450 425 500 403 367 392 481 
18 464 475 447 479 346 329 358 
19 451 459 454 451 425 381 415 
20 429 439 392 472 413 425 435 
21 424 426 431 465 371 386 391 
22 400 402 395 510 406 363 435 
23 333 396 509 470 404 396 
24 454 422 450 407 389 385 378 
25 402 419 365 390 363 359 361 
26 452 438 407 316 316 324 355 
27 369 374 459 480 431 394 427 
28 421 356 430 450 478 549 557 
29 382 558 501 499 473 478 452 
30 444 360 414 344 345 355 
31 378 338 468 416 357 256 
32 480 447 455 460 374 384 
M 439.6 431.3 464.6 434.4 402.5 399.4 409.6 
















































巾の変化で高度の減少（維i少の高度なもの） ( ;, l例
第3節
栓球数の変動
Post i Post 3～5w 
164×103 103X 103 
268 : 89 
222 I 248 
254 I 134 
156 . 160 
147 228 
196 ; 222 
145 I 200 
256 ; 180 


















































































定で減少傾向の認められたのは症例1,2, 7, 8,10, 1, 縁部における高まりも低く，その巾も縮少しており，





















































1 1nc類似進行l ! I ↓ 
2 ilk頬似進行1 ↓ ｜ ↓ 
3 1Bor. I十He1 I 
4 I Ile → 1 
4 • Ile+ II ， →｜ 
5 : Bor. Il I ↑ 1 
6 1 Bor. Il ＇ → ！ 
7 i Bor. II ↓ 1 
8 i Bor. I ， ↓ 
9 I Ile 1 
10 I Ile+ II 
11 I Bor. II 
12 I Ila 
12 I Bor. II 
13 I Bor. II 
14 i Bor. II 
15 I Bor. II 
16 ', Bor. I 
17 ; Bor. I
18 I I 
19 ! Ile 
20 ! Ilc+Ill 
21 I Bor. Il 
22 ' Bor. II 
23 ; Bor. II 
24 I Bor. II 
25 1 Ile+ II 
26 j Ilc+Ill 
幻 iBor. I 
28 , Ilc+lll 
29 [ Bor. Il 
30 I Ilc+Ilb 
31 ' Ilc+Ilb 





































































































































































































部 位 lA 1AMI M MAIMc:cM CE 
症例数 i10 I 4 i 16 ! 2 1 1 1 I 1 
表9（，時
大智 ！周
5 1 1 
部位 ｜前墜 l後墜｜ 小轡 l
症例 数 ｜ 7 11 : 11 
肉眼的診断では早期癌が14病変で， l型l,Ila型l,

















癌死はStage I, Eにはなく， Stage Eの症例8
の 1例のみで，本例の癌の占居部位はA，小 前後で




















































































































































































































































































tu bu I are 
tubulare 。
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cinoma tubulare mucocellulareおよび Grade %と GradeIlbの病変が増加している．
Ilbを示した症例13,14の計4病変であった． Grade Oは粘膜層および粘膜下組織でも同様に
3) 筋層における MMCの効果 Grade Oであった痕例17である．
筋層にまで癌の浸潤が認められた症例は2ll丙'flで． Gradellbの9病変中Adenocarcinomatubulare 
Grade Oはl病変4.8%,Grade Iは6病変28.6°o, muconodulareが4病変， Adenocarcinomatubu-






























































3 I 60 I Ad. tub. mucocel. [ sm I 16 [ 4×1 I 2 
Ad. tub. muconod. I pm 
5 I 72 I Ad. tub. I s2 
8 Ad. tub. muconod. 60 
11 
12 
Ad. tub. mucocel. scirr. 
Ad. tub. mucocel. 
Ad. tub. 
Ad. tub. 
Ad. tub. medull. 
Ad. tub. mucocel. 







29 Ad. tub. mucocel. scirr. 60 
32 60 Ad目 tub. scirr. 
18 6 x 2 
1×4 


















6 x 1 
1×2 
4 x 1 
6 x 3 
S2 29 3×2 



































??? ?? ? ??
全域 I D3 
全域 I D3 
全域 I DJ 
全域 I D3 
全域 I D3 
髄洞 i D3 
髄洞 I DJ 




辺縁洞 I DJ 
辺縁洞 I DJ 
全域 I D2 
全域 I D2 
辺縁洞 I Di
髄洞・辺縁洞 IDJ 
部分 I DJ 
全域 I DJ 
辺縁洞 I DJ 
辺縁洞 I D3 
辺縁洞 I DJ 
全域 I D2 
部分 I D2 
全域 I D2 
全域 I Di
全域 i Di
部分 I D2 
胃癌に対する抗癌剤の術前投与に関する研究
表14 リンパ節転移陰性症例
































7 I 60 I Ad. tub. scir. 
9 I 60 I Ad. tub. m山 ocel.
















































D2 03 : D2 I 03 













~~.B~：竺＂W':.r・ ~~r.·~f~:i言ぐー 、＞：，，~ ;;•'l.,·-:<···'·'T/.:\l，＇，＇立山、E,<;;;. 
写真 5. 症例27. リンパ節番号1.HE染色 70>< 
髄洞転移，腺管状腺癌の転移がリンパ鴻胞を取ま
く髄洞に限局して認められる．
" , 一－，、‘． ． 一－‘ 













Grade Ilaは症例7,2, 24の3例， GradeIは症例 2,
10, 11,16, 19, 30の6例で， GradeOは症例17の1例
に認められた．これに対して，レ線ならひに内視鏡検
査で不変とされた16病変中 GradeIlb は症例12,13, 
14,15の4病変で， GradeIlaは症例 6,＇乙21,26, 28 


































































































































































































































が多く， craterの縮少した病変13病変中 GradeIlb 
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